{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dementia/prescribing-information/memantine-hydrochloride/","result":{"pageContext":{"chapter":{"id":"45d5f01b-c1c2-53dc-91b4-8f7a90983fd5","slug":"memantine-hydrochloride","fullItemName":"Memantine hydrochloride","depth":2,"htmlHeader":"<!-- begin field de93a140-a88c-438c-9291-844d63df55fe --><h2>Memantine hydrochloride</h2><!-- end field de93a140-a88c-438c-9291-844d63df55fe -->","summary":"","htmlStringContent":"<!-- begin item 9f1a99fd-e150-430e-a124-d0022d4b2020 --><!-- begin field e4446543-9faa-40d2-ac1c-87455b19855d --><ul><li>For people who are not taking memantine, prescribers should only start treatment with these on the advice of a clinician who has necessary knowledge and skills. <ul><li>Once a decision has been made to start an AChE inhibitor or memantine, the first prescription may be made in primary care.</li><li>For people with an established diagnosis of Alzheimer's disease who are already taking an AChE, primary care prescribers may start treatment with memantine without taking advice from a specialist clinician. </li><li>Ensure that local arrangement for prescribing, supply and treatment review follow the NICE guideline on medicines optimisation. <ul><li>Treatment may be continued in primary care under a shared care protocol. </li></ul></li></ul></li><li>For further information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/dementia/management/follow-up-of-confirmed-dementia-in-primary-care/#specialist-treatment\">Specialist dementia treatment</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2018b</a>] </p><!-- end field e4446543-9faa-40d2-ac1c-87455b19855d --><!-- end item 9f1a99fd-e150-430e-a124-d0022d4b2020 -->","topic":{"id":"de9cbb4d-2d69-500f-be27-dc83f76dc3ba","topicId":"2491e3e7-cc21-42b9-8972-e54804b4782f","topicName":"Dementia","slug":"dementia","lastRevised":"Last revised in October 2020","chapters":[{"id":"af834011-0042-530a-8f9a-acd5828e0a34","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a0360b83-4555-5079-897f-12b2d555c1af","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"52cd8e36-39cd-5259-8819-bd96087b0265","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"60bd6b27-027f-56a6-a018-a1d694a6a2f3","slug":"changes","fullItemName":"Changes"},{"id":"7ced1224-30c2-5f30-9caf-3764f3665ae4","slug":"update","fullItemName":"Update"}]},{"id":"fae05cff-ad98-52fa-89b4-b97369195d59","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2f3b4bd3-e7cf-5492-afe0-0a5b230eab7e","slug":"goals","fullItemName":"Goals"},{"id":"9104785e-e491-5ca3-b3d3-7e951385bce9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a9c56eb4-bc0e-51cc-b486-a54c23906bc0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ebf62eba-a4cd-536c-8c9f-c9505b0e7482","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a71b8dc2-79f8-5d24-b668-c792abc5a624","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c87232ba-6926-5ff2-98d2-f8839b0c0d37","slug":"nice-quality-standards","fullItemName":"NICE Quality Standards"}]},{"id":"825c29c3-9d55-54ae-b54d-8ee2ac796e97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"46c6316f-eec0-580a-80ec-2112d2f0122f","slug":"definition","fullItemName":"Definition"},{"id":"f485482d-0d4e-52cb-9df4-3548bc72a566","slug":"causes","fullItemName":"Causes"},{"id":"87101d89-6073-57cc-b247-48be586ef185","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"58f6ec5a-c90b-5e64-a476-fc9fca39c6ae","slug":"prevalence","fullItemName":"Prevalence"},{"id":"994469e3-f824-5f48-b755-7f74dd360680","slug":"prognosis","fullItemName":"Prognosis"},{"id":"718f9ed4-d725-5f6e-a86f-5df88719cd52","slug":"complications","fullItemName":"Complications"}]},{"id":"366bcbe3-827a-5e08-9d81-8de84e46fefd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"565bac2a-ada3-5b0a-ab7d-6681501b2c4a","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"4c0fe55f-40c9-5a1c-8cf3-1ec8d88406d5","slug":"assessment","fullItemName":"Assessment"},{"id":"ef7780bd-8e94-5f95-870f-92ab930c4365","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3069f5e5-519f-50ec-81b7-c8948a5b3117","fullItemName":"Management","slug":"management","subChapters":[{"id":"c6c0cbc2-18fc-5bf8-973d-bc38b9001f28","slug":"suspected-dementia","fullItemName":"Scenario: Suspected dementia"},{"id":"6320a2da-e9d6-5f57-94d9-0433261edf89","slug":"follow-up-of-confirmed-dementia-in-primary-care","fullItemName":"Scenario: Follow up of confirmed dementia in primary care"},{"id":"343a59fa-439e-5ab9-9d3b-28a893d55d2f","slug":"management-of-end-stage-dementia","fullItemName":"Scenario: Management of end-stage dementia"}]},{"id":"9a2639de-07aa-5fe3-8f09-5c005f9c29dd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"58ed8441-e3ca-566e-9afb-92a5ba60b1dd","slug":"haloperidol","fullItemName":"Haloperidol"},{"id":"67092bd7-2ab4-5e8b-8ead-5301454da4a8","slug":"acetylcholinesterase-inhibitors","fullItemName":"Acetylcholinesterase inhibitors"},{"id":"f4ced652-a6de-5e19-ae37-6de43dfd8104","slug":"lorazepam","fullItemName":"Lorazepam"},{"id":"45d5f01b-c1c2-53dc-91b4-8f7a90983fd5","slug":"memantine-hydrochloride","fullItemName":"Memantine hydrochloride"}]},{"id":"1e87c908-2ab5-5cba-8d6a-958c03f7a6cd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fc7a2bcf-854b-5ca4-9b02-2dcaaebe1162","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7bcb26a3-cc69-5201-9fd9-6353e27b412f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0c383917-58d0-5036-8217-5d9fd81cb2cb","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fdb8af52-aeee-52bd-be79-c5534939d42f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a9f930f3-f8b6-5c8f-b8ca-b3155e0c23d3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"668c11fa-1873-58d4-b0e2-3eab90e8fbff","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"67c4aef9-fbf4-5bf6-8dc5-c501f74b1fe3","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9a2639de-07aa-5fe3-8f09-5c005f9c29dd","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"6134d163-dfe9-5a51-8400-9cfcae271b11","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 1c5e2437-f843-477d-a7a8-4b5b8ec81337 --><h3>What dose of memantine hydrochloride is usually prescribed?</h3><!-- end field 1c5e2437-f843-477d-a7a8-4b5b8ec81337 -->","summary":"","htmlStringContent":"<!-- begin item c532fb24-bf09-42ab-80e2-4fc0d5000547 --><!-- begin field 8c2cc29c-5307-4993-8fc7-751491742c29 --><p><strong>Memantine hydrochloride should <em>always</em> be initiated and supervised by specialists experienced in the management of dementia. However, treatment may be continued in primary care under a shared-care protocol. Specialist advice should be sought if a change in dose is required or if the treatment needs to be stopped.</strong></p><ul><li>As a general guide:<ul><li>The usual dose for most people is, initially 5 mg once daily, increased in steps of 5 mg at weekly intervals to a maximum of 20 mg daily.</li><li>For people with renal impairment, the dose will depend on the estimated glomerular filtration rate (eGFR):<ul><li>If eGFR is 30–49 mL/minute/1.73 m2, the dose should be reduced to 10 mg daily. If well tolerated after at least 7 days, the dose can be increased in steps to 20 mg daily.</li><li>If eGFR is 5–29 mL/minute/1.73 m2, the dose should be reduced to 10 mg daily.</li><li>If eGFR is less than 5 mL/minute/1.73 m2, memantine should be avoided.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]</p><!-- end field 8c2cc29c-5307-4993-8fc7-751491742c29 --><!-- end item c532fb24-bf09-42ab-80e2-4fc0d5000547 -->","subChapters":[]},{"id":"9d301d9e-f5d1-5a83-b682-78c7fbaafca8","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field f4c8b143-c2b2-4543-a4c2-8010384a2783 --><h3>What are the possible adverse effects of memantine hydrochloride?</h3><!-- end field f4c8b143-c2b2-4543-a4c2-8010384a2783 -->","summary":"","htmlStringContent":"<!-- begin item 3e0c6539-8b2f-4f43-8e47-8be279d0f923 --><!-- begin field 2ab9111b-4997-4fe7-a6a6-45941f352e36 --><p><strong>Memantine hydrochloride should <em>always</em> be initiated and supervised by specialists experienced in the management of dementia. However, treatment may be continued in primary care under a shared-care protocol. Specialist advice should be sought if a change in dose is required or if the treatment needs to be stopped.</strong></p><ul><li><strong>Adverse effects of memantine include:</strong><ul><li>Commonly, constipation, hypertension, dyspnoea, headache, dizziness, and drowsiness.</li><li>Less commonly, vomiting, thrombosis, heart failure, confusion, fatigue, hallucinations, and abnormal gait.</li><li>Very rarely, seizures, pancreatitis, psychosis, depression, and suicidal ideation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]</p><!-- end field 2ab9111b-4997-4fe7-a6a6-45941f352e36 --><!-- end item 3e0c6539-8b2f-4f43-8e47-8be279d0f923 -->","subChapters":[]},{"id":"73447298-d182-5c41-99c8-c16006716c73","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 54286aab-a5cc-4725-a0e4-4d64e7494c02 --><h3>What are the contraindications and cautions with memantine hydrochloride?</h3><!-- end field 54286aab-a5cc-4725-a0e4-4d64e7494c02 -->","summary":"","htmlStringContent":"<!-- begin item 7dd85d51-16b0-4d06-baac-e4ed06754481 --><!-- begin field e2155100-0612-40ed-b77c-7836599760b8 --><p><strong>Memantine hydrochloride should<em> always</em> be initiated and supervised by specialists experienced in the management of dementia. However, treatment may be continued in primary care under a shared-care protocol. Specialist advice should be sought if a change in dose is required or if the treatment needs to be stopped.</strong></p><ul><li><strong>Contraindications</strong><ul><li>Hypersensitivity to the active substance or to any of the excipients, including people with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.</li><li>Severe hepatic impairment.</li><li>Severe renal impairment — memantine hydrochloride should be avoided if estimated glomerular filtration rate (eGFR) is less than 5 mL/minute/1.73 m2.</li></ul></li><li><strong>Cautions</strong><ul><li>History of convulsions or predisposing factors for epilepsy. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]</p><!-- end field e2155100-0612-40ed-b77c-7836599760b8 --><!-- end item 7dd85d51-16b0-4d06-baac-e4ed06754481 -->","subChapters":[]},{"id":"caee3964-1f4f-5350-b970-a6696321836a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field c4e0c691-9326-4bed-af4f-32a879dbfeb3 --><h3>What are the possible drug interactions with memantine hydrochloride?</h3><!-- end field c4e0c691-9326-4bed-af4f-32a879dbfeb3 -->","summary":"","htmlStringContent":"<!-- begin item 7c6e6476-6538-4722-bb45-b34396e23a78 --><!-- begin field 454f76b6-9cc7-4d8b-9215-2dcd3514b29e --><p><strong>Memantine should <em>always</em> be initiated and supervised by specialists experienced in the management of dementia. However, treatment may be continued in primary care under a shared-care protocol. Specialist advice should be sought if a change in dose is required, the treatment needs to be stopped, or an interacting drug is to be prescribed.</strong></p><ul><li><strong>Possible drug interactions with memantine include:</strong><ul><li><strong>Antimuscarinics</strong> — memantine possibly enhances effects of antimuscarinics.<ul><li>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase adverse effects such as dry mouth, urine retention, and constipation.</li><li>Concomitant use can also lead to confusion in elderly people.</li></ul></li><li><strong>Antipsychotics </strong>— memantine possibly reduces effects of antipsychotics.</li><li><strong>Baclofen and dantrolene</strong> — memantine possibly modifies the effects of these drugs. A dose adjustment may be necessary. </li><li><strong>Dopaminergics</strong> — memantine possibly enhances effects of dopaminergic drugs such as amantadine.</li><li><strong>N-methyl-D-aspartate (NMDA)-antagonists</strong> (such as amantadine, ketamine or dextromethorphan) — there is an increased risk of central nervous system toxicity with memantine. Avoid concomitant use. </li><li><strong>Selegiline</strong> — memantine possibly enhances effects of selegiline. </li><li><strong>Warfarin</strong> — memantine possibly enhances anticoagulant effect of warfarin. Monitor international normalized ratio (INR) closely during concurrent use.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]</p><!-- end field 454f76b6-9cc7-4d8b-9215-2dcd3514b29e --><!-- end item 7c6e6476-6538-4722-bb45-b34396e23a78 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}